Yau T K, Chan A, Cheung P Sy
Hong Kong Breast Cancer Foundation, 22/F, Jupiter Tower, No. 9, Jupiter Street North Point, Hong Kong.
Hong Kong Med J. 2017 Feb;23(1):19-27. doi: 10.12809/hkmj154754. Epub 2016 Oct 24.
The treatment of ductal carcinoma in situ has been widely reported in the western and other Asian countries, but the relevant data in Hong Kong are relatively limited. This study aimed to evaluate the latest detection and treatment pattern for ductal carcinoma in situ in Hong Kong so as to guide planning of future service provision.
This was a retrospective case series study. A total of 573 patients who registered with the Hong Kong Breast Cancer Registry, and were diagnosed and treated in Hong Kong from January 2001 to December 2011 were reviewed.
Compared with invasive breast cancer patients, patients with ductal carcinoma in situ were younger (median, 48.6 vs 50.3 years; P<0.001), had a higher education level (P<0.001), had a higher total monthly family income (P<0.001), and more common breast-screening habits (P<0.001). Significantly more patients with ductal carcinoma in situ underwent breast-conserving surgery than their invasive cancer counterparts (55.8% vs 36.7%; P<0.001). The percentage of screen-detected ductal carcinoma in situ was relatively lower than that reported in other studies, but was still much higher than that in invasive breast cancer patients (29.0% vs 4.7%; P<0.001). Screen-detected patients with ductal carcinoma in situ tended to choose a private hospital instead of a public hospital for treatment (P=0.05) and to undergo breast-conserving surgery (P=0.02). With a median follow-up of 3 years, the crude local recurrence rate after mastectomy and breast-conserving surgery was 0.4% and 3.3%, respectively; 44% of recurrent tumours had developed invasive components. No regional recurrence, distant recurrence, or cancer-related deaths were recorded.
In the absence of a population-based breast screening programme in Hong Kong, ductal carcinoma in situ is more frequently found in the higher social classes and managed in the private sector. The clinical outcome of ductal carcinoma in situ is excellent and more than half of the patients can be successfully managed with breast-conserving surgery.
导管原位癌的治疗在西方和其他亚洲国家已有广泛报道,但香港的相关数据相对有限。本研究旨在评估香港导管原位癌的最新检测和治疗模式,以指导未来服务提供的规划。
这是一项回顾性病例系列研究。对2001年1月至2011年12月在香港乳腺癌登记处登记、在香港诊断并接受治疗的573例患者进行了回顾。
与浸润性乳腺癌患者相比,导管原位癌患者更年轻(中位数分别为48.6岁和50.3岁;P<0.001),教育水平更高(P<0.001),家庭月总收入更高(P<0.001),且有乳房筛查习惯的情况更常见(P<0.001)。接受保乳手术的导管原位癌患者明显多于浸润性癌患者(55.8%对36.7%;P<0.001)。筛查发现的导管原位癌百分比相对低于其他研究报道的水平,但仍远高于浸润性乳腺癌患者(29.0%对4.7%;P<0.001)。筛查发现的导管原位癌患者倾向于选择私立医院而非公立医院进行治疗(P=0.05)并接受保乳手术(P=0.02)。中位随访3年,乳房切除术后和保乳手术后的粗局部复发率分别为0.4%和3.3%;44%的复发性肿瘤已发展为浸润性成分。未记录到区域复发、远处复发或癌症相关死亡。
在香港缺乏基于人群的乳房筛查计划的情况下,导管原位癌在社会经济地位较高的阶层中更常见,并在私立部门进行管理。导管原位癌的临床结果良好,超过一半的患者可通过保乳手术成功治疗。